WO2017211314A1 - Procédé pour détecter la présence d'une substance mycobactérienne dans un échantillon à l'aide d'un antigène de mannosyl-phosphocétide immobilisé - Google Patents

Procédé pour détecter la présence d'une substance mycobactérienne dans un échantillon à l'aide d'un antigène de mannosyl-phosphocétide immobilisé Download PDF

Info

Publication number
WO2017211314A1
WO2017211314A1 PCT/CN2017/087542 CN2017087542W WO2017211314A1 WO 2017211314 A1 WO2017211314 A1 WO 2017211314A1 CN 2017087542 W CN2017087542 W CN 2017087542W WO 2017211314 A1 WO2017211314 A1 WO 2017211314A1
Authority
WO
WIPO (PCT)
Prior art keywords
antigen
antigens
immobilised
sample
solid substrate
Prior art date
Application number
PCT/CN2017/087542
Other languages
English (en)
Inventor
Johannes Theodorus CASTROP
Original Assignee
Kei International Limited
Tomorrows Ip Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from NL2016914A external-priority patent/NL2016914B1/en
Priority claimed from NL2016913A external-priority patent/NL2016913B1/en
Priority claimed from NL2017204A external-priority patent/NL2017204B1/en
Application filed by Kei International Limited, Tomorrows Ip Limited filed Critical Kei International Limited
Priority to US16/307,427 priority Critical patent/US20190302114A1/en
Priority to RU2018146447A priority patent/RU2018146447A/ru
Priority to CN201780047054.5A priority patent/CN109791145A/zh
Priority to BR112018075462-5A priority patent/BR112018075462A2/pt
Priority to EP17809753.1A priority patent/EP3469364A4/fr
Publication of WO2017211314A1 publication Critical patent/WO2017211314A1/fr

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria

Definitions

  • the present invention relates to a solid substrate comprising an antigen immobilised to said substrate which antigen is capable of binding to an antibody which is indicative for the presence of mycobacterial material in a human or animal, and a method of detecting the presence of antibodies against mycobacterial material in a sample which applies said solid substrate comprising said immobilised antigen.
  • the invention also relates to a biosensor comprising said solid substrate.
  • Mycobacterium tuberculosis is a pathogenic bacterial species in the family Mycobacteriaceae and the causative agent of most cases of tuberculosis (TB) .
  • TB is still one of the leading causes of death in many low and middle income countries. In addition, more and more cases are reported of multi-drug resistant TB.
  • TB skin test also called the Mantoux tuberculin skin test
  • TB blood tests also called interferon-gamma release assays or IGRAs
  • chest radiography X-ray
  • ARB acid-fast-bacilli
  • Sputum smear microscopy (also referred to as smear test) is a common method for diagnosis of pulmonary tuberculosis in low and middle income countries where most TB cases occur. Although it is a simple, rapid and inexpensive technique which is used in areas with a very high prevalence of tuberculosis, there are significant limitations in its performance. For instance, the sensitivity is severely compromised when the bacterial load is less than 10,000 Mycobacterium tuberculosis organisms/ml sputum sample. A person that tests positive in a smear test (smear positive person) thus has a very high bacterial load and will thus be in a very advanced stage of TB.
  • smear positive persons In smear positive persons it is usually clear at first sight that the person suffers from an illness. In such advanced stages, often no successful treatment is possible anymore. On the other hand, no conclusion can be drawn if a person tests negative in a smear test (smear negative person) , because that person could suffer from TB in a less advanced stage, which is associated with a lower bacterial load.
  • smear negative persons In smear negative persons it is usually not clear at first sight that the person suffers from an illness.
  • the smear test also gives poor results in extra-pulmonary tuberculosis, pediatric tuberculosis and in patients co-infected with HIV and tuberculosis.
  • the inventor has observed in samples derived from healthy subjects a high degree of binding of materials contained in these samples to immobilised mycolic acid antigens when used as sole type of antigens, which indicates that samples derived from healthy subjects contain materials which bind to mycolic acid antigens, but which are not indicative for tuberculosis. This may lead to a false positive outcome.
  • a subject actually suffers from tuberculosis, the problem arises that if materials that are not indicative for tuberculosis bind to immobilised mycolic acid antigens in a detection test, a high background binding signal is produced. This high background signal may obscure the signal derived from the actual markers for tuberculosis. So, there is also the risk of false negative results.
  • the inventor therefore considers that there is room for improvement with respect to the sensitivity of detection of tuberculosis.
  • the present invention therefore aims to overcome the problems that derive from the binding of materials that are not indicative for tuberculosis to immobilised mycolic acid antigens and to improve the sensitivity of detection of tuberculosis.
  • the aim of the invention has been achieved by the provision of immobilised mannosyl phosphoketides which are capable of binding to antibodies which are indicative for the presence of mycobacterial material with high specificity and a method of detecting the presence of antibodies against mycobacterial material in a sample which applies said immobilised antigen.
  • the invention relates to a solid substrate, comprising a mannosyl phosphoketide antigen immobilised to said solid substrate, wherein said immobilised antigen is capable of binding to an antibody which is indicative for the presence of mycobacterial material in a human or animal, wherein the antigen is a compound represented by the following formula (I) ,
  • Y is an integer between 1 and 10
  • X + is a cation or absent and R is a hydrocarbon group, preferably an alkyl group, wherein the antigen is optionally modified with one or more functional groups that enable immobilisation to said solid substrate, and enantiomers, diastereoisomers, and mixtures thereof.
  • the invention relates to a method of detecting antibodies against mycobacterial material in a sample, a comprising the steps of:
  • the invention in a third aspect relates to a biosensor comprising said solid substrate comprising an immobilised antigen as defined in the paragraph before the previous paragraph.
  • the inventor has surprisingly found that if a solid substrate with the immobilised mannosyl phosphoketide antigens in accordance with formula I is used in a method for detecting a marker for tuberculosis a very high tuberculosis specific binding of antibodies to these antigens is detected.
  • the signal derived from the actual markers for tuberculosis is significantly less obscured by a background signal than when immobilised mycolic antigens are used, so that the signal derived from the actual markers for tuberculosis becomes more pronounced. This way the invention provides a significant improvement with regard to the sensitivity of detection of markers for tuberculosis.
  • the solid substrate with said immobilised mannosyl phosphoketide antigens in accordance with the invention is used in a method for detecting a marker for tuberculosis a very high tuberculosis specific binding of antibodies to these antigens is detected in particular in case of samples derived from patients that were tested smear positive, so that in an stage of the disease wherein fast and reliable diagnosis is of utmost importance, a fast diagnosis is provided.
  • the immobilised mannosyl phosphoketide antigens of the invention perform very well when applied to samples derived from patients co-infected with HIV and tuberculosis.
  • Fig. 1 shows a diagram with ELISA results using mycolic acid immobilised on ELISA plates (IgM as secondary antibody) .
  • Fig. 2 shows a diagram of ELISA results using tuberculosinyl adenosine antigens immobilised on ELISA plates (IgM as secondary antibody) .
  • Fig. 3 shows a diagram of ELISA results using diacyl glycolipid antigens immobilised on ELISA plates (IgM as secondary antibody) .
  • Fig. 4 shows a diagram of ELISA results using mycolic acid immobilised on ELISA plates (IgG as secondary antibody) .
  • Fig. 5 shows a diagram of ELISA results using mannosyl phosphoketide antigens immobilised on ELISA plates (IgG as secondary antibody) .
  • Fig. 6 shows a diagram of ELISA results using diacyl glycolipid antigens according to formula (XIII) immobilised on ELISA plates.
  • a mannosyl phosphoketide antigen is immobilised on a solid substrate.
  • This antigen is capable of binding to an antibody which is indicative for the presence of mycobacterial material in a human or animal.
  • mycobacterial material in this context is meant material derived from Mycobacterium tuberculosis which leads to generation of antibodies in a human or animal. The presence of this material indicates tuberculosis.
  • the mannosyl phosphoketide antigen immobilised on the substrate of the invention is a compound represented by the following formula (I) ,
  • Y is an integer between 1 and 10
  • X + is a cation or absent
  • R is a hydrocarbon group
  • the antigen is optionally modified with one or more functional groups that enable immobilisation to said solid substrate, and enantiomers, diastereoisomers, and mixtures thereof.
  • X+ is a cation it is preferred that it is a proton or metal cation, such as a Na or K cation.
  • hydrophobic tail of the mannosyl phosphoketide antigen is rather short. This makes the antigens more soluble in aqueous solutions and thus easier in use.
  • the increased hydrophilicity that results from relatively short hydrocarbon chains makes the detection surface or sensor surface to which the antigens are immobilised more hydrophilic. Because of this, interactions of antibodies in the antigen occur easier and the speed of the detection will be enhanced. Moreover, it will be easier to synthesize the antigens in case synthetic antigens are used.
  • Y preferably is an integer between 3 and 9, preferably between 4 and 8, most preferably wherein Y is 5.
  • R preferably is an alkyl group. It is preferred that R is a C1-C15 alkyl, preferably a C5 alkyl or a C7 alkyl, preferably wherein R is an n-C5-alkyl or an n-C7-alkyl. It is preferred that R is an n-C7-alkyl.
  • Y may be modified with one or more functional groups that enable immobilisation to said solid substrate.
  • R may be modified with one or more functional groups that enable immobilisation to said solid substrate.
  • mannosyl phosphoketide antigen antigen is a ⁇ -mannosyl phosphomycoketide, optionally modified with one or more functional groups that enable immobilisation to said solid substrate.
  • a highly preferred ⁇ -mannosyl phosphomycoketide is
  • X + is a cation (such as metal cation, e.g. K + or Na + or proton) or absent and R is n-C 7 H 15 or n-C 5 H 11 , optionally modified with one or more functional groups that enable immobilisation to a solid substrate, and enantiomers, diastereoisomers, and mixtures thereof. It is highly preferred that R is n-C 7 H 15 as this is the form that commonly occurs in Mycobacterium tuberculosis. ⁇ -mannosyl phosphomycoketide antigens lead to significant improvement with regard to the sensitivity of detection of markers for tuberculosis.
  • ⁇ -mannosyl phosphomycoketide molecules exist in Mycobacterium tuberculosis they can be isolated from the bacteria. In this case the natural antigen is used and, depending on the substrate to which it is to be immobilised, modified for immobilisation purposes if necessary.
  • the levels of ⁇ -mannosyl phosphomycoketides in Mycobacteria are rather low, much lower than for instance the levels of mycolic acid. Therefore it is more advantageous to synthesize ⁇ -mannosyl phosphomycoketide molecules, either fully chemically or with help of a production organism by means of transgenic expression. This saves considerable costs. It is therefore preferred that the ⁇ -mannosyl phosphomycoketide is synthetic. Synthesis can be performed for instance as described in Van Summeren et al., 2006.
  • the solid substrate to which the mannose phosphoketide antigen of the invention is immobilised may contain other immobilised molecules as well.
  • compounds may be immobilised to control the hydrophobicity/hydrophilicity of the solid substrate.
  • the substrate’s surface may become too hydrophobic for efficient binding of antibodies.
  • This may be obtained by co-immobilisation of hydrophilic molecules distributed between the antigens or by immobilization of the antigens onto hydrophylic molecules that are immobilized to the solid substrate.
  • Such hydrophilic molecules may for instance be PEG or mPEG.
  • the solid substrate may contain any combination of antigens that are capable of binding to antibodies which are indicative for tuberculosis. For instance a combination of different antigens that fall within the scope of formula I or a combination of one or more antigens that fall within the scope of formula I and other molecules.
  • mannose phosphoketide antigens in addition to the mannose phosphoketide antigens as described above, other antigens that are capable of binding to an antibody which is indicative for the presence of mycobacterial material in a human or animal can also be used in combination with the mannose phosphoketide antigens.
  • These other antigens may be co-immobilised to the same solid substrate as the mannose phosphoketide antigens or be provided on separate solid substrates. The latter enables detection of binding of antibodies to the different types of antigens on separate sections or in separate compartments of a biosensor or in sequence.
  • Such antigens may include mycolic acid derived antigens, tuberculosinyl adenosine antigens, diacyl glycolipid antigens and derivatives of these antigens in any combination.
  • antigens may be isolated from Mycobacterium tuberculosis or be synthetic, i.e. obtained by full chemical synthesis or by synthesis in a production host which is not a Mycobacterium, for instance by transgenic expression, e.g. in E. coli, followed by isolation and optional further purification steps.
  • mannosyl phosphoketide antigens are used and/or immobilised together with further antigens that are capable of binding to an antibody which is indicative for the presence of mycobacterial material in a human or animal
  • these further antigens are said diacyl glycolipids or derivatives thereof optionally modified with one or more functional groups that enable immobilisation to a solid substrate, because the inventor has found high tuberculosis specific binding of antibodies to these antigens in particular in case of samples derived from patients that were tested smear negative.
  • diacyl glycolipid antigens in this application is meant to refer to diacylated trehalose structures as defined in the following structures (III) to (XI) .
  • diacyl glycolipids which are in fact diacylated trehalose antigens and therefore can also be referred to as diacylated trehalose antigens, or derivatives thereof can be defined as a compound represented by the following formula (III) ,
  • R 2 and R 3 are independently chosen from H, SO 3 H, SO 3- or SO 3- /M + , wherein M + is a cation, preferably a metal cation such as Na + or K + ;
  • R 2’ and R 3’ are acyl groups, wherein the antigen is optionally modified with one or more functional groups that enable immobilisation to a solid substrate.
  • the diacyl glycolipids as described herein also include enantiomers, diastereoisomers, and mixtures the compounds of formula (III) .
  • R 2’ and R 3’ identical or different, may be
  • X is independently chosen from an unsaturated or saturated linear or branched hydrocarbon chain, suitably an alkyl group, optionally substituted with one or more substituents and/or modified with one or more functional groups.
  • R 2 is SO 3- , SO 3 H or SO 3-/ M + , wherein M + is a cation and R 3 is H. It is preferred that in case R 2 is SO 3-/ M + that the cation is Na + or K + .
  • R 2 and R 3 are H.
  • X is a saturated linear hydrocarbon chain optionally substituted with one or more substituents and/or modified with one or more functional groups and wherein in the other of R 2’ and R 3’ X is a saturated branched hydrocarbon chain optionally substituted with one or more substituents and/or modified with one or more functional groups.
  • one of R 2’ and R 3’ is a group represented by the following formula (IV) :
  • R 4 is a linear saturated hydrocarbon chain with formula C n H n+1 , wherein n is an integer between 1 and 20, optionally modified with one or more functional groups, and wherein Y is an integer between 1 and 10, and wherein R 5 is H or OH, and the other one of R 2’ and R 3’ is a linear saturated hydrocarbon chain with formula C n H n+1 , wherein n is an integer between 1 and 20, optionally modified with one or more functional groups.
  • the acyl chains represented by R 2’ and R 3’ are relatively short. This makes the antigens more soluble in aqueous solutions and thus easier in use.
  • the increased hydrophilicity that results from relatively short acyl chains makes the detection surface or sensor surface to which the antigens are immobilised more hydrophilic. Because of this, interactions of antibodies in the antigen occur easier and the speed of the detection will be enhanced. Moreover, it will be easier to synthesize the antigens in case synthetic antigens are used.
  • R 4 may be a linear saturated hydrocarbon chain with formula C n H n+1 , wherein n is an integer between 1 and 10, such as between 1 and 9, such as between 1 and 8, such as between 1 and 7, such as between 1 and 6 such as between 1 and 5 such as between 1 and 4 such as between 1 and 3, such as 1, 2, 3, 4, 5, 6, 7, 8 or 9, optionally modified with one or more functional groups, and wherein Y is an integer between 1 and 10, such as between 1 and 5, such as between 1 and 4, such as between 1 and 3, such as 1, 2, 3, 4 or 5, optionally modified with one or more functional groups.
  • n is an integer between 1 and 10, such as between 1 and 9, such as between 1 and 8, such as between 1 and 7, such as between 1 and 6 such as between 1 and 5 such as between 1 and 4 such as between 1 and 3, such as 1, 2, 3, 4, 5, 6, 7, 8 or 9, optionally modified with one or more functional groups
  • Y is an integer between 1 and 10, such as between 1 and 5, such as between 1 and 4, such as between 1 and 3, such as 1, 2, 3, 4
  • R 2’ and R 3’ in this respect may be a linear saturated hydrocarbon chain with formula C n H n+1 , wherein n is an integer between 1 and 15, such as between 1 and 14, such as between 1 and 13, such as between 1 and 12, such as between 1 and 11, such as between 1 and 10, such as between 1 and 9, such as between 1 and 8, such as between 1 and 7, such as between 1 and 6 such as between 1 and 5 such as between 1 and 4 such as between 1 and 3, such as between 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 optionally modified with one or more functional groups.
  • a suitable antigen in this respect would for example be compound (V) :
  • This exemplary molecule is modified with a thio acetate group to enable immobilisation to a solid substrate, for instance a silica substrate or gold substrate.
  • An antigen with a thiol group can be directly immobilised to gold.
  • the substrate suitably can be coated with a silane active group to which the thiol of the modified antigen can bind.
  • the diacyl glycolipid antigen is present in Mycobacterium, tuberculosis it may be isolated from Mycobacterium tuberculosis.
  • the antigen may be synthesized, for instance by a method as adapted from what is described in EP 1 950 218 A1. If the antigen is not present in Mycobacterium tuberculosis it may be modified from an antigen isolated from Mycobacterium tuberculosis or synthesized.
  • the further antigen is a diacylated sulfoglycolipid (Ac 2 SGL) as found in Mycobacterium tuberculosis, optionally modified with one or more functional groups.
  • Ac 2 SGL is 2-palmitoyl-3-hydroxyphthioceranoyl-2’-sulfate- ⁇ - ⁇ ’-D-trehalose or 2-stearoyl-3-hydroxyphthioceranoyl-2’-sulfate- ⁇ - ⁇ ’-D-trehalose, optionally modified with one or more functional groups.
  • Ac 2 SGL molecules feature a trehalose 2’-sulfate core, and are diacylated with either a palmitic or stearic residue at the 2-position and hydroxyphthioceranic acid, with varying length and methyl substituents, at the 3-position, for instance compound (VI) :
  • R 2 is SO 3- , SO 3 H or SO 3-/ M + , wherein M + is a kation, preferably a metal cation, preferably Na + or K + .
  • SO 3-/ Na + moiety may also be SO 3- , SO 3 H and Na+ may also be another kation such as K + .
  • diacyl glycolipid antigens as defined above may be represented by formula (X) :
  • R2’and R3’ are in formula (X) as defined for formula (III) above. It is preferred that one or both acyl chains herein are modified to enable immobilisation to a solid substrate. It is in particular preferred to use a compound as represented by formula (XI) :
  • acyl chains of the compound of formula (XI) may be substituted for any chain as defined in formula (IV) , and the chains may be optionally modified to enable enable immobilisation to a solid substrate.
  • Suitable modification include the incorporation of a thio group on one of the acyl chains or the incorporation of a unsaturated bond at the end of one of the acyl chains, e.g. a double bond.
  • Suitable examples of such modified molecules include compounds according to formula (XII) , which has an alkene group at the terminus of one of the acyl chains or (XIII) which has a thiol group at the terminus of one of the acyl chains.
  • alkyl chains of the compound of formulae (XII) and (XIII) may be substituted for any chain having the formula C n H n+1 or formula (IV) modified with the above shown alkene or thiol group.
  • the diacyl glycolipid antigens provide a means for obtaining high sensitivity of detection of markers for tuberculosis. Very high tuberculosis specific binding of antibodies to these antigens is detected in case of samples derived from patients that were tested smear negative. This makes it possible to diagnose TB in an early stage, in which there is a higher chance for successful treatment without complications compared to TB in a late stage.
  • these particular antigens perform excellent when applied to samples derived from patients co-infected with HIV and tuberculosis.
  • tuberculosinyl adenosine antigens may be used for the purposes of the invention, optionally in further combination with the above described diacyl glycolipid antigens.
  • tuberculosinyl adenosine antigens are compounds represented by the following formula (XIV) ,
  • R 1 is H or a group with formula (XV)
  • R 2 is absent or a group with formula (XV) , provided that one of R 1 and R 2 is a group with formula (XV) , R 3 and R 4 are selected independently from hydrogen, OH, an acyl chain, a carboxylic acid group comprising an acyl chain, in any combination thereof, wherein the antigens are optionally modified with one or more functional groups that enable immobilisation to a solid substrate, and enantiomers, diastereoisomers of the antigens, and mixtures thereof.
  • R 4 is OH, and even more preferred that R 4 and R 3 are OH.
  • R 1 may be a group of formula (XV) and R 2 may be absent. In other embodiments R 1 may be H and R 2 may be a group of formula (XV) . In case R 2 is a group of formula (XV) , the nitrogen to which it is attached carries a positive charge.
  • the functional groups that enables immobilisation to a solid substrate is preferably included in the group of formula (XV) .
  • R 3 or R 4 are or comprise an acyl group it is preferred that only one of R 3 and R 4 is or comprises an acyl group, or in particular a fatty acid group.
  • Acyl groups preferably have a suitable length and hydrophobicity to enable immobilisation to a solid substrate.
  • the acyl chain may be modified with a functional group to enable immobilisation to a solid substrate.
  • An acyl chain may be a mycolic acid chain as described in WO 2014/210327.
  • the antigen of formula (XIV) has an acyl chain that the acyl chain is rather short. This makes the antigens more soluble in aqueous solutions and thus easier in use.
  • the increased hydrophilicity that results from relatively short hydrocarbon chains makes the detection surface or sensor surface to which the antigens are immobilised more hydrophilic. Because of this, interactions of antibodies in the antigen occur easier and the speed of the detection will be enhanced. Moreover, it will be easier to synthesize the antigens in case synthetic antigens are used.
  • the acyl chain may be a linear or branched C 1 -C 20 chain, such as a C 5 -C 20 chain.
  • the antigen of formula (XIV) is represented by a compound of formula (XVI) or (XVII) , optionally modified with one or more functional groups that enable immobilisation to a solid substrate.
  • the antigen in accordance with formula (XIV) is selected from the group of 1-tuberculosinyladenosine (as in formula (XVI)) , 1-tuberculosinyl-2’-deoxyadenosine, 1-tuberculosinyl-O-acetyladenosine or a combination thereof.
  • These compounds occur naturally in Mycobacterium tuberculosis bacteria and can be isolated therefrom.
  • the natural antigen may be used and, depending on the substrate to which it is to be immobilised, modified for immobilisation purposes if necessary.
  • the levels of these compounds in Mycobacteria are rather low, much lower than for instance the levels of mycolic acid. Therefore, it is more advantageous to chemically synthesize these molecules, or to synthesize them in a production host micro-organism followed by isolation and optional further purification steps. This saves considerable costs. It is therefore preferred that these compounds are synthetic.
  • Synthetic antigens in accordance with formula (XIV) may for instance be synthetized in accordance with the method described in Buter et al., 2016.
  • tuberculosinyl adenosine antigens as defined above are used in a method for detecting a marker for tuberculosis a very high tuberculosis specific binding of antibodies to these antigens is detected.
  • the signal derived from the actual markers for tuberculosis is significantly less obscured by a background signal than when immobilised mycolic antigens are used, so that the signal derived from the actual markers for tuberculosis becomes more pronounced. This way the invention provides a significant improvement with regard to the sensitivity of detection of markers for tuberculosis.
  • tuberculosinyl adenosine antigens as defined above are used in a method for detecting a marker for tuberculosis in combination with other types of antigens that are capable of binding to an antibody which is indicative for the presence of mycobacterial material in a human or animal, a more reliable indication is provided that the subject from which the sample is derived has active tuberculosis.
  • antigens such as the other antigens described herein, although they may serve as reliable markers of the presence of antibodies against mycobacterial material, may not distinguish between an active tuberculosis infection (such as in smear negative, smear positive, HIV-positive/tuberculosis co-infected, paediatric and extra-pulmonary patients) and an inactive tuberculosis infection (such as in a Bacillus Calmette–Guérin (BCG) vaccinated subject or a subject cured from a tuberculosis infection) .
  • BCG Bacillus Calmette–Guérin
  • tuberculosinyl adenosine antigens as defined above are not properly detectable in samples derived from subjects vaccinated with a BCG vaccine or from subjects cured from a tuberculosis infection. In other words, if a sample contains a measurable amount of antibodies against tuberculosinyl adenosine antigens as defined above this is an indication of active tuberculosis. This makes it possible to distinguish in a tuberculosis test between subjects with active tuberculosis and subjects wherein the infection is inactive.
  • mycolic acid derived antigens may be used for the purposes of the invention, optionally in further combination with the above described diacyl glycolipid antigens or tuberculosinyl adenosine antigens or both of said diacyl glycolipid antigens or tuberculosinyl adenosine antigens.
  • the mycolic acid derived antigens as referred to in the present application may be derived from mycobacteria selected from virulent and pathogenic mycobacteria.
  • the term mycolic acid derived antigen is to be understood as a compound comprising a mycolic acid residue which is capable of binding to anti-mycolic acid antibodies.
  • the mycolic acid antigen is derived from Mycobacterium tuberculosis.
  • Said mycolic acid derived antigen may be at least one selected from the group of mycolic acid, cord factor, chemically modified mycolic acid, chemically modified cord factor, a synthetic mycolic acid derivative, a synthetic cord factor derivative.
  • the mycolic acid derived antigen may suitably be selected from one or more of mycolic acids obtained from natural sources, synthetically prepared mycolic acids, sulfur-containing mycolic acids, structural analogues of mycolic acids, and mycolic acid wax esters.
  • the mycolic acid derived antigen also includes salts and/or esters of these derivatives.
  • Natural sources of mycolic acid derivatives include the cell walls of mycobacteria such as Mycobacterium tuberculosis include mixtures of different classes of compounds and different mycolic acid homologues, often as derivatives in which they are bonded to the wall of the cell.
  • Esters of mycolic acid derivatives can also be used such as esters of alcohols (e.g. monohydric alcohols and polyhydric alcohols) and sugar esters.
  • Sugar esters are particularly preferred.
  • Sugar esters include esters with a monosaccharide, disaccharide or an oligosaccharide. Said saccharides may conveniently include sugar units based on hexoses and/or pentoses. Glucose esters are suitable examples of these esters.
  • Further suitable sugar esters are trehalose esters, including trehalose monomycolates and trehalose dimycolates. For instance cord factors, which are trehalose monomycolates or trehalose dimycolates are well known examples of sugar esters that are suitable. These compounds occur in nature as complex mixtures of different classes of mycolic acids and of different homologues within each class.
  • Suitable semi-synthetic derivatives include semi-synthetic cord-factors which may be prepared by attaching mycolic acids to the sugar group. These semi-synthetic factors however still contain mixtures of different homologue. Therefore particular suitable mycolic acid derivatives for use in the context of the present invention are synthetic cord factors, for example the synthetic cord factors described in WO 2010/08667, i.e.
  • Salts of mycolic acid derivatives can also be used, for instance ammonium salts, or alkali metal and alkaline earth metal salts.
  • Sulfur-containing mycolic acids and/or esters or salts thereof may also be used. These compounds are analogues of natural mycolic acid compounds containing sulfur.
  • Mycolic acid wax esters comprise a cyclopropyl group or an alkene and an internal ester group and can be isolated from natural sources or prepared synthetically.
  • Suitable compounds for use in the detection method of the invention are described inter alia in WO 2016/024116.
  • the mycolic acid antigen may be in a form selected from homogenous and heterogenous compound mixtures.
  • the mycolic acid derived antigen may for instance be used in combination with a phospholipid such as phosphatidylcholine.
  • antigens either the mannosyl phosphoketide antigens or optional further antigens
  • the way antigens are immobilised to a substrate depends on the characteristics of the substrate to which the antigens are immobilised.
  • Some substrates allow immobilisation of antigens without modification, for instance by means of hydrophobic interaction of one or both of the hydrophobic carbon chains, such as acyl chains, of the antigen with the substrate. This would for instance be possible if the antigens are immobilised to the surface of an ELISA plate, a nitrocellulose membrane or a PVDF membrane.
  • the most convenient immobilisation method is direct physical absorption of the antigen to the assay membrane.
  • a functional group in this application is therefore to be understood as a group that enables immobilisation of the antigen to a solid substrate.
  • These functional groups are preferably added to one or both of the hydrophobic carbon chains of the antigens, e.g. the alkyl chains of the mannosyl phosphoketide antigens.
  • Such a functional group can for instance be a thio group, an amine group, an aldehyde group, a double bond (i.e. an alkene group) or any other suitable group.
  • tuberculosinyl adenosine antigens may be added to one or more of the hydrophobic carbon chains of the antigens, e.g. the alkyl chains. Alternatively, functional groups may be added to the nitrogen or amine of the adenosine moiety. Alternatively, functional groups may be added to the tuberculosinyl tail with formula (II) of the antigen.
  • the functional groups are preferably added to one or more of the hydrophobic carbon chains of the antigens, e.g. the alkyl chains of the mannosyl phosphoketide antigens.
  • the functional groups are preferably added to one or both of the hydrophobic carbon chains of the antigens, i.e. the acyl chains of the diacyl glycolipid antigens.
  • a functional group can for instance be a thio group, an amine group, an aldehyde group or any other suitable group.
  • modified substrates include:
  • NHS ester-activated support materials wherein NHS esters are reactive groups formed by EDC activation of carboxylate molecules to react with primary amines on the antigen;
  • CDI-activated support materials wherein carbonyl diimidazole (CDI) activates hydroxyls to form reactive imidazole carbamates that form carbamate linkages with primary amine-containing/modified antigens;
  • Antigens can be immobilised or “coupled” directly to solid support material by formation of covalent chemical bonds between particular functional groups on the (modified) antigen (e.g., primary amines, sulfhydryls, carboxylic acids, aldehydes) and reactive groups on the support material. It is also possible that antigens are immobilised non-covalent binding such as hydrophobic interaction or via streptavidin-biotin coupling. Various coupling methods are possible.
  • thio coupling, amine coupling and carbonyl-reactive immobilisation methods which involve coupling through carbonyl (sugar) groups where cis-diols can be oxidized with sodium periodate to create aldehydes as sites for covalent immobilisation.
  • a silica based substrate may be modified with a silane derivative containing a free amine group, e.g. aminopropyltriethoxysilane or aminomethoxysilane. This free amine group reacts spontaneously with a thiol modified antigen to form a covalent bond. This does not require complicated protocols.
  • a thiol cysteamine monolayer may be applied to the gold substrate, the free amine of the thiol cysteamine may than be applied in a spontaneous coupling reaction with a thiol modified antigen. This would not require complicated protocols.
  • coupling may be based on various mechanisms. An unmodified antigen may be immobilised to the membrane with its hydrophobic tail (s) as discussed above, but other mechanisms are also possible.
  • Such mechanisms include covalent attachment of thiolated antigen to an epoxide-functionalized nitrocellulose membrane, attachment of a biotinylated antigen through a nitrocellulose-binding streptavidin anchor protein, and fusion of an antigen to a novel nitrocellulose-binding anchor protein for direct coupling and covalent attachment through an epoxide thiol linkage using a functionalized nitrocellulose membrane immobilisation.
  • the antigens are immobilised to a solid substrate which can be exposed to a sample derived from a human or animal so that binding of antibodies to the immobilised antigens can be determined, either qualitatively or quantitatively or both.
  • solid substrate means the same as “solid surface” or ” solid support” .
  • the solid substrate may be a sensing surface or substrate of a detection device or a detection surface or substrate in a detection assay.
  • the substrate to which the antigens are immobilised may be a sensing surface of a surface plasmon resonance device, electrochemical impedance spectroscopy device, isothermal titration calorimetry device, bio-layer interferometry device, optical gratings device, photonic crystal device, acoustic resonant profiling device, or quartz crystal microbalance device or a detection surface in an enzyme-linked immunosorbent assay (ELISA) , a Western blotting assay, radioactive labelling assay, photospectrometric assay, immunofluorescence, immunoprecipitation assay, immunocytochemistry assay, immunohistochemistry assay, voltametric detection assay, amperometric detection assay or electrochemical impedance spectroscopy assay.
  • ELISA enzyme-linked immunosorbent assay
  • the immobilised solid substrate of the invention can be used in the method of the invention which comprises the steps of:
  • one or more samples from a human or animal may be compared to a sample from a human or animal which is confirmed to be healthy and to a sample from a human or animal which is confirmed to have tuberculosis.
  • all samples in one analysis undergo the same treatment in accordance with the steps of the method of the invention.
  • the high specificity of the mannosyl phosphoketide antigens for tuberculosis specific antibodies and the associated lower risk of false positives makes it even possible to reliably diagnose whether a person has tuberculosis without the necessity of a reference sample obtained from a healthy subject.
  • the high specificity of the mannosyl phosphoketide antigens for tuberculosis specific antibodies and the associated lower risk of false positives also make it possible to reliably diagnose whether a person has tuberculosis without the necessity to divide a sample from a human or animal into two sample fractions of which one is exposed to antigens before the two fractions are exposed to a detection substrate with antigens such as for instance described in WO 2005/116654 or WO 2013/186679, where mycolic acids are used as immobilised antigens.
  • the method of the invention is therefore less difficult to perform and leads to fast and reliable diagnosis.
  • a sample from a human or animal is provided.
  • the sample is derived from a human or animal which is suspected of having active tuberculosis, for instance a human or animal that had contact with someone suffering from tuberculosis or who resides in an area or travelled to an area with high prevalence of tuberculosis.
  • the sample is derived from a smear positive person, i.e. derived from a person in which the bacterial load is 10.000 or more mycobacteria/ml sputum.
  • the sample may be obtained by any regular means of obtaining blood from a subject.
  • samples may be used that have been collected at an earlier stage, stored until use under suitable conditions and provided at a suitable moment.
  • a sample may be used in the detection method of the invention on the spot, i.e. as a point of care test.
  • the sample is preferably a blood derived sample.
  • the sample may be a whole blood sample, a plasma sample or a serum sample.
  • Blood serum is blood plasma without clotting factors and is preferred as plasma.
  • the word plasma in this application may therefore as well refer to (blood) serum.
  • Serum is preferred because it contains less different materials than blood plasma, which may lead to aspecific interactions or unwanted biological activity.
  • serum may have a lower viscosity than blood plasma. Using serum therefore may circumvent the need for diluting a sample, which saves time and materials.
  • the sample is a whole blood sample
  • the sample is preferably pre-filtered or separated to plasma or serum.
  • a suitable filter for such a pre-filtering step is a 0, 2 micron filter.
  • Plasma or serum in this application may therefore also refer to diluted plasma or serum.
  • a dilution of the blood or plasma may therefore be implemented in the method of the invention, such as 5 to 10 x dilution, a 10 to 20 x dilution, a 20 to 50 x dilution, a 50 to 100 x dilution, a 250 to 5000 x dilution, a 750 to 1250 x dilution, such as for instance a 5 x, 10 x, 20 x, 50 x, 100 x, 200 x, 500 x, 4000 x, 2000 x or 1000 x dilution.
  • such dilution may take place before the step of separating the plasma from the blood step (filter step or separating step) .
  • dilution may take place after the filter step.
  • Dilution may be performed with any suitable diluent, for example a PBS based buffer, such as a blocking buffer.
  • a PBS based buffer such as a blocking buffer.
  • Such buffer may for example be a PBS/AE buffer comprising NaCl, KCl, KH 2 PO 4 , Na 2 HPO 4 and EDTA in water at physiological pH.
  • Such buffer may be a PBS based buffer consisting of 8.0 g NaCl, 0.2 g KCl, 0.2 g KH 2 PO 4 , and 1.05 g Na 2 HPO 4 per liter of double distilled, deionized water containing 1 mM EDTA and 0.025% (m/v) sodium azide which is adjusted to pH 7.4.
  • the whole blood sample or plasma or serum may be further diluted with agents that prevent blood clotting, such as EDTA, heparine or citrate.
  • a detergent may be added in low concentration to the blood/plasma/serum to avoid sticking of components of the test system used.
  • At least part of the sample is exposed to a solid substrate carrying the immobilised antigen, i.e. to a detection substrate, and binding of antibodies to the antigen is detected.
  • the method of the invention encompasses but is not limited to exposure and detection of binding to only one type of antigens, i.e. the mannose phosphoketide antigens as described above
  • the sample is exposed to a combination of the mannose phosphoketide antigens as described above and one or more types of antigens selected from the group of mycolic acid derived antigens, tuberculosinyl adenosine antigens and diacyl glycolipid antigens as defined above.
  • the method comprises detecting the presence of antibodies against mycobacterial material in a sample comprising the steps of:
  • a first type of antigens which are the mannose phosphoketide antigens as described above and one or more further type of antigens, wherein said one or more further type antigens comprise antigens selected from the group of mycolic acid derived antigens, tuberculosinyl adenosine antigens and diacyl glycolipid antigens as defined above,
  • binding of an antibody to said first and further types of antigen is indicative for the presence of mycobacterial material in a human or animal.
  • the sole type of antibody antigen used in the method, solid substrate and biosensor of the invention is said mannose phosphoketide type antigen.
  • multiple types of antigens are used in the method, solid substrate and biosensor of the invention in accordance with the combinations A-G as described in the following paragraph.
  • antigens mannose phosphoketide antigens mycolic acid derived antigens, tuberculosinyl adenosine antigens and diacyl glycolipid antigens defined in this application, no other types of antigens are used as immobilised antigens in the method, solid substrate and biosensor.
  • Possible combinations are combinations comprising or consisting of 2, 3 or 4 types of antigens as follows (mannose phosphoketide antigens and mycolic acid derived antigens, tuberculosinyl adenosine antigens and diacyl glycolipid antigens are as defined above) :
  • combination B or C may be preferred.
  • Combination B may be preferred because the mannose phosphoketide antigens perform particularly well in case samples derived from smear positive persons are tested and tuberculosinyl adenosine antigens perform particularly well in providing a reliable indication that the subject from which the sample is derived has active tuberculosis.
  • the use of these antigens which each result in a specific output upon exposure to a sample from a subject suspected of having tuberculosis enables to provide information about the nature and/or disease state of the subject.
  • Combination C may be preferred because the mannose phosphoketide antigens perform particularly well in case samples derived from smear positive persons are tested, while the diacyl glycolipid antigens perform particularly well in case samples derived from smear negative persons are tested. This enables very sensitive detection of tuberculosis, irrespective of the bacterial load in a patient.
  • Mannose phosphoketide antigens + diacyl glycolipid antigens + tuberculosinyl adenosine antigens.
  • combination F In case of a combination of three antigens combination F is preferred, because very sensitive detection of tuberculosis, irrespective of the bacterial load in a patient is possible because of the use of mannose phosphoketide antigens and diacyl glycolipid antigens, and because tuberculosinyl adenosine antigens perform particularly well in providing a reliable indication that the subject from which the sample is derived has active tuberculosis. In this respect this combination of three antigens provides an excellent way of detecting tuberculosis and determining whether the tuberculosis is active or not. With this combination, it does not matter what the disease state is of the person from which the sample is derived.
  • the sample may thus be derived from a smear negative, smear positive, HIV- positive/tuberculosis co-infected, paediatric and extra-pulmonary patient or from a person with inactive tuberculosis infection, such as in a BCG vaccinated person or a person cured from a tuberculosis infection) .
  • a person with inactive tuberculosis infection such as in a BCG vaccinated person or a person cured from a tuberculosis infection
  • Mannose phosphoketide antigens + diacyl glycolipid antigens + tuberculosinyl adenosine antigens + mycolic acid derived antigens may be used in combination with the other antigens.
  • mycolic acid involves a risk of false positive/negative signal
  • detection of binding of antibodies in the sample to mycolic acid derived antigens provides an additional indication of whether or not a person is infected with tuberculosis or not. This further enhances the reliability of the method of the invention.
  • the mannose phosphoketide antigen may be a ⁇ -mannosyl phosphomycoketide
  • the tuberculosinyl adenosine antigen may be 1-tuberculosinyladenosine
  • the mycolic acid derived antigen may be mycolic acid
  • the diacyl glycolipid antigen may be the molecule according to formula (XIII) , wherein the hydrophobic tails of these molecules may be modified for immobilisation.
  • a sample is tested negative for antibodies against phosphomycoketide antigens, and/or negative for antibodies against diacyl glycolipid antigens and/or negative against for antibodies against mycolic acid; and also negative for antibodies against 1-tuberculosinyl adenosine antigens
  • the patient is diagnosed healthy. If a sample is tested positive for antibodies against phosphomycoketide antigens, and/or positive for antibodies against diacyl glycolipid antigens and/or positive against for antibodies against mycolic acid; but negative for antibodies against tuberculosinyl adenosine antigens, the patient can be diagnosed as a BCG vaccinated subject or a subject cured from tuberculosis.
  • a sample is tested positive for antibodies against phosphomycoketide antigens, and/or positive for antibodies against diacyl glycolipid antigens and/or positive against for antibodies against mycolic acid antigens; and positive for antibodies against tuberculosinyl adenosine antigens, the patient is diagnosed as having active tuberculosis.
  • a sample may be divided in subsamples before exposure, each subsample dedicated to be exposed for a particular type of antigen. Simultaneous detection may be performed with one or more substrate carrying multiple types of antigens or with multiple substrates each carrying a particular type of antigen, for instance in a bioreactor comprising different compartments each containing a solid substrate with one type of antigen.
  • the first type of antigens and one or more further type of antigens may be immobilised on a solid substrate.
  • the invention also relates to a solid substrate which comprises a combination of immobilised antigens according to any of the combinations A-G above.
  • solid substrates may thus comprise:
  • antigens capable of binding to an antibody which is indicative for the presence of mycobacterial material in a human or animal such as a solid substrate with ⁇ -mannosyl phosphomycoketide antigens and Ac 2 SGL antigens immobilised thereto; a solid substrate with 1-tuberculosinyladenosine antigens and ⁇ -mannosyl phosphomycoketide antigens immobilised thereto; or a solid substrate with ⁇ -mannosyl phosphomycoketide antigens and mycolic acid antigens immobilised thereto;
  • a solid substrate with three types of antigens capable of binding to an antibody which is indicative for the presence of mycobacterial material in a human or animal such as a solid substrate with 1-tuberculosinyladenosine antigens, Ac 2 SGL antigens and ⁇ -mannosyl phosphomycoketide antigens immobilised thereto; or a solid substrate with 1-tuberculosinyladenosine antigens, mycolic acid antigens and ⁇ -mannosyl phosphomycoketide antigens immobilised thereto; or a solid substrate with ⁇ -mannosyl phosphomycoketide antigens, 1-Ac 2 SGL antigens and mycolic acid antigens immobilised thereto; or
  • a solid substrate with four types of antigens capable of binding to an antibody which is indicative for the presence of mycobacterial material in a human or animal such as a solid substrate with 1-tuberculosinyladenosine antigens, Ac 2 SGL antigens, ⁇ -mannosyl phosphomycoketide antigens and mycolic acid antigens immobilised thereto. It is preferred in this respect that a solid substrate has 1-tuberculosinyladenosine antigens, Ac 2 SGL antigens and ⁇ -mannosyl phosphomycoketide antigens immobilised thereto, and optionally also mycolic acid.
  • a sample is tested negative for antibodies against ⁇ - mannosyl phosphomycoketide, and/or negative for antibodies against Ac 2 SGL and/or negative against for antibodies against mycolic acid; and also negative for antibodies against 1-tuberculosinyladenosine
  • the patient is diagnosed healthy. If a sample is tested positive for antibodies against ⁇ -mannosyl phosphomycoketide, and/or positive for antibodies against Ac 2 SGL and/or positive against for antibodies against mycolic acid; but negative for antibodies against 1-tuberculosinyladenosine, the patient is diagnosed as a BCG vaccinated subject or a subject cured from tuberculosis.
  • a sample is tested positive for antibodies against ⁇ -mannosyl phosphomycoketide, and/or positive for antibodies against Ac 2 SGL and/or positive against for antibodies against mycolic acid; and positive for antibodies against 1-tuberculosinyladenosine, the patient is diagnosed as having active tuberculosis.
  • the sample is exposed to the solid substrate with the immobilised antigen or multiple types of immobilised antigens as described above; followed by detecting binding of antibodies to the antigens immobilised to said substrate.
  • Binding of the antibodies to the immobilised antigens can be detected by means of any assay that involves measurement of change of mass on the substrate, change of refractive index, change of entropy, change of enthalpy, viscosity change, temperature change, colour change etc.
  • Detection of binding of antibodies to the antigen on the detection substrate may take place with any suitable detection method, including simple visual detection or methods that include voltametrical, amperometrical or any electrochemical detection.
  • Detection of binding of antibodies to the antigen on the detection substrate may take place in real time or by means of an end-point assay.
  • Suitable real time detection assays include surface plasmon resonance or electrochemical impedance spectroscopy, isothermal titration calorimetry, bio-layer interferometry, optical gratings, photonic crystal, acoustic resonant profiling, quartz crystal microbalances.
  • the solid substrate carrying the antigen may be silica based, such as substrates based on silicium dioxide.
  • the antigens are preferably modified at one or both of the acyl chains with a functional group that enables immobilisation.
  • Silica based substrates are particularly useful when ring resonance technology is used to detect binding of antibodies to the immobilised antigens.
  • the detection is carried out using a biosensor chip using a Si-based ring resonator. This enables the method of the invention to be carried out with a very compact device.
  • the solid substrate is gold based.
  • Gold based substrates are particularly useful when surface plasmon resonance or electrochemical impedance spectroscopy are used to detect binding of antibodies to the immobilised antigens.
  • the detection of binding of antibodies and/or other material to the antigen on the detection substrate may be carried out in an automated device.
  • Various automated devices will be known to the person skilled in the art and the skilled person will be able to select suitable software means to determine the degree or extent of binding to the detection substrate.
  • Detection of binding of antibodies to the antigen on the detection substrate may also take place by means of an end-point assay.
  • end-point assay is to be understood as an assay wherein the outcome of interest is the end result after a fixed assay incubation period, in contrast to the aforementioned real-time assay.
  • An end-point detection assay may for instance detect changes to levels of color, fluorescence, absorbance or luminescence at the end of a test.
  • Suitable end-point assays include enzyme-linked immunosorbent assay (ELISA) , Western blotting, radioactive labelling assay, photospectrometric assay, immunofluorescence, immunoprecipitation, immunocytochemistry, immunohistochemistry, amperometric or voltametric detection assays, or electrochemical impedance spectroscopy.
  • ELISA enzyme-linked immunosorbent assay
  • Western blotting radioactive labelling assay
  • photospectrometric assay immunofluorescence, immunoprecipitation
  • immunocytochemistry immunohistochemistry
  • amperometric or voltametric detection assays or electrochemical impedance spectroscopy.
  • an end-point assay detection takes place by means of an immunogold filtration assay.
  • the detection substrate is a microporous membrane, preferably a nitrocellulose membrane or a PVDF membrane, to which an antigen is immobilised.
  • secondary antibodies that bind the heavy chain of the primary antibodies that bind to the immobilised antigens.
  • Many suitable secondary antibodies are commercially available.
  • the secondary antibody may be coupled to nanoparticles or beads, for instance gold beads, or associated with liposomes.
  • Examples of secondary antibodies may be protein A or G, possibly conjugated with an enzyme that enables detection.
  • a particular suitable technique or detecting the binding of antibodies to the immobilised antigens on the detection substrate is the so-called immunogold filtration assay (IGFA) , and in particular the dot immunogold filtration assay (DIGFA) .
  • IGFA immunogold filtration assay
  • DIGFA dot immunogold filtration assay
  • Immunogold filtration assays are methods combining ELISA and immunogold technique and are methods in which a sample to be assayed is allowed to filtrate through a microporous membrane, preferably a nitrocellulose membrane, and is captured by a capture probe coated on the membrane.
  • a colloidal gold-labelled probe is allowed to filtrate through the microporous membrane in the same manner.
  • the antigen is immobilised on a microporous membrane, preferably a nitrocellulose membrane.
  • the optionally pre-treated samples can be applied to the membrane.
  • colloidal gold-labelled second antibodies can be added onto the membrane to have gold particle aggregation in the antigen-antibody reaction place.
  • aggregation visible red or brown spots are formed.
  • the intensity of the spot is proportional to the amount of reactions between antigen and antibody, i.e. to the amount of antibodies in the sample. In other words a sample from a person suffering from tuberculosis will result in a more intense spot than a sample from a person which is healthy.
  • Immunogold filtration assays are simple and rapid detection methods because no instruments are required except a membrane and the reagents and the results can be observed by the naked eye within a few minutes.
  • the microporous membrane may be for example a nitrocellulose membrane, a cellulose acetate membrane or a PVDF membrane with a suitable pore diameter.
  • nitrocellulose is used.
  • a suitable pore diameter is 0, 2 to 5 ⁇ m.
  • the membrane may be washed with a suitable buffer, for example a PBS based buffer.
  • a PBS based buffer may for example be a PBS/AE buffer comprising NaCl, KCl, KH 2 PO 4 , Na 2 HPO 4 and EDTA in water at physiological pH.
  • Such buffer may be a PBS based buffer consisting of 8.0 g NaCl, 0.2 g KCl, 0.2 g KH 2 PO 4 , and 1.05 g Na 2 HPO 4 per liter of double distilled, deionized water containing 1 mM EDTA and 0.025%(m/v) sodium azide which is adjusted to pH 7.4.
  • the antigen may be immobilised to the microporous membrane in a dot wise manner.
  • a DIGFA assay the samples are also applied to the membrane in the form of dots.
  • the colloidal gold-labelled second antibodies are added in the form of dots.
  • a DIGFA assay is particularly preferred because at different spots on several membranes various antigens deriving from various mycobacterial strains may be immobilised. This way it becomes possible to provide information on which mycobacterial strain a patient is infected with.
  • Another advantage of using DIGFA is that samples derived from different persons can be compared in one test, because DIGFA enables fast and reliable detection of antibody-antigen interaction in an unlimited amount of spots, depending on the size of the membrane.
  • the detection of binding of antibodies and/or other material to the immobilised antigens may be carried out in an automated device.
  • Various automated devices will be known to the person skilled in the art and the skilled person will be able to select suitable software means to quantify the degree or extent of binding on the detection substrates.
  • the detection of binding of antibodies and/or other material to the immobilised antigen may be performed by a visual detection technique or any other suitable detection technique.
  • detection by means of the end-point assay takes place visually, preferably with the naked eye. This has the advantage of easy detection without the need for expensive and complicated detection technology.
  • binding of antibody antibodies and/or other material to the immobilised antigens may be assessed by means of the naked eye.
  • a visual signal e.g. the red staining in case a DIGFA assay is applied as end-point assay, may also be detected with help of a mobile app, i.e. a computer program designed to run on mobile devices such as tablet computers or smart phones.
  • a mobile app i.e. a computer program designed to run on mobile devices such as tablet computers or smart phones.
  • an app can be used that is designed to compare the binding signal between different samples or sample fractions and which indicates whether the human or animal from which the sample originated has tuberculosis.
  • the method of the invention may comprise additional steps that are advantageous for the sensitivity of the method.
  • the method may contain further steps of exposing the sample to molecules that have affinity for molecules in the sample that lead to a binding signal which is not specific for tuberculosis in order to scavenge away these non-specific molecules.
  • the method may also contain further steps of dividing the sample.
  • the high specificity of the mannosyl phosphoketide antigens of the invention for tuberculosis specific antibodies and the associated lower risk of false positives also make it possible to reliably diagnose whether a person has tuberculosis without the necessity to divide a sample from a human or animal into two sample fractions of which one is exposed to antigens before the two fractions are exposed to a detection substrate with antigens. Nevertheless, the mannosyl phosphoketide antigens of the invention would be suitable in such a method.
  • the method of the invention therefore may be a real-time method comprising the steps of:
  • step iii) exposing the sample fraction exposed in step iii) to a solid test substrate which is a solid substrate as described above for the first aspect of the invention and exposing the sample fraction exposed in step iv) to a solid control substrate which which has the same composition as the solid test substrate;
  • step vii) comparing the degree or extent of binding between the test and control substrates, any observed lesser binding to the test substrate being an indicator of the presence of antibodies to the immobilised antigen in the sample that indicates tuberculosis in the human or animal from which the samples originated, wherein the antigens immobilised to the solid substrate of step iii) comprise at least one type, preferably all the types of antigens that are immobilised to the solid test and control substrates.
  • the method of the invention may be an end-point method of detecting antibodies against mycobacterial material in a sample
  • step iii) exposing at least part of the sample fraction exposed in step iii) to a solid test substrate which is a substrate which is a solid substrate as described above for the first aspect of the invention and exposing the sample fraction exposed or stored in step iv) to a solid control substrate which has the same composition as the solid test substrate;
  • step vii) comparing the degree or extent of binding between the test and control substrates, any observed lesser binding to the test substrate being an indicator of the presence of antibodies to the immobilised antigen in the sample that indicates tuberculosis in the human or animal from which the samples originated, wherein the antigens immobilised to the solid substrate of step iii) comprise at least one type, preferably all the types of antigens that are immobilised to the solid test and control substrates.
  • the substrate to which the antibody is immobilised in step iii) of these embodiments is in general not made of the same material as the test/control substrate.
  • the substrate in step iii) may be made of any material that is inert for non-specific binding of molecules of the sample. Such materials include polytetrafluorethylene (e.g. ) , polypropylene, polyetherketone (PEEK) and polyethylene.
  • the test and control substrates in these embodiments are sensing surfaces or substrates of a detection device or detection surfaces or substrates in a detection assay as discussed above.
  • the immobilised mannosyl phosphoketide antigens and optional one or more further immobilised antigens selected from the group of mycolic acid derived antigens, tuberculosinyl adenosine antigens, diacyl glycolipids in combinations A-G as described above can be incorporated in a biosensor for use in the method of the invention.
  • the biosensor may further comprise a combination of one or more further antigens selected from the group of mycolic acid derived antigens, tuberculosinyl adenosine antigens, diacyl glycolipids as defined in any of combinations A-G above, immobilised on one or more substrates.
  • the antigens may be immobilised to one and the same substrate mixed or at separate locations or at different substrates in the biosensor. Using separate locations or separate substrates enables analysis of the nature of a possible tuberculosis infection for instance for obtaining an indication whether the tested person has active tuberculosis.
  • the biosensor can be any biosensor which is suitable for use in the method according to the invention.
  • the biosensor may comprise a silica based substrate with an immobilised mannosyl phosphoketide antigen and a Si ring resonator. Such a biosensor can be used for ring resonance.
  • the substrates of the chambers of the biosensor are gold based.
  • Gold based substrates are particularly useful when surface plasmon resonance or electrochemical impedance spectroscopy are used to detect binding of antibodies to the immobilised mannosyl phosphoketide antigens.
  • the invention also encompasses any other biosensor comprising the solid substrate of the invention.
  • Immobilised diacyl glycolipid antigen in accordance with formula (XIII) was immobilised via the terminal thio group.
  • Serum derived from humans that were known to be suffering of tuberculosis was derived from both smear positive (Patients 1-9 (+) ) and smear negative patients (Patients 11-18 (-) ) .
  • Samples of patients 19-40 tested for anti-TbAd antibodies are a random selection of smear negative and positive patients.
  • samples were used derived from healthy humans (Healthy 1, 2 and 3) . Fractions of 0, 5 ml were obtained and transferred each to a 0, 2 micron spin filter and centrifuged at 10000 g. The flow-through was diluted 1: 20 in blocking buffer.
  • Fig. 1 shows the results of an ELISA test with rabbit anti-human IgM HRP as secondary antibody using immobilised mycolic acid. It is clear that very high background signal is obtained in the healthy persons (healthy 1 and 2, white bars) . As these persons were confirmed to be healthy and samples from these persons thus do not contain antibodies against mycobacterial material, this signal is the result of materials that are unrelated to tuberculosis that do bind to mycolic acid and lead to an ELISA signal. The samples derived from smear negative patients (patients 11-18 (-) , grey bars) show absorbance signals which do not significantly exceed the signal of the healthy persons.
  • Fig. 2 shows ELISA tests with rabbit anti-human IgM HRP as secondary antibody that were performed with immobilised 1-tuberculosinyladenosine.
  • the background signal obtained in the healthy persons appears to be markedly lower than that i s obtained by using mycolic acids as immobilised antigens.
  • Fig. 2 show that if these immobilised antigens are used in a method for detecting a marker for tuberculosis a very high tuberculosis specific binding of antibodies to these antigens is detected, regardless of whether the samples are derived from smear positive (patients 1-9 (+) , black bars) or smear negative persons (patients 10-18 (-) , dark grey bars) as the signals of both are similar the signals of the random samples (19-40) .
  • This high specificity is clearly not the case when mycolic acids immobilised to a solid substrate are applied.
  • the signal derived from antibodies against 1-tuberculosinyladenosine appears to be significantly less obscured by a background signal than when immobilised mycolic antigens are used. This results in a significant improvement with regard to the sensitivity of detection of markers for tuberculosis.
  • Fig. 3 shows that when ELISA tests with rabbit anti-human IgM HRP as secondary antibody were performed with immobilised Ac 2 SGL, the background signal obtained in the healthy persons (healthy 1 and 2, white bars) appears to be markedly lower.
  • the samples derived from smear positive patients (patients 1-9 (+) , black bars) show absorbance signals which are higher than the signal of the healthy persons, thus confirming the presence of specific antibodies that indicate tuberculosis. This effect is even more pronounced in the samples derived from smear negative patients (patients 11-18 (-) , grey bars) which show absorbance signals which are significantly higher than the signal of the healthy persons.
  • Fig. 4 shows the results of an ELISA test with rabbit anti-human IgG HRP using immobilised mycolic acid. It is clear that a high background signal is obtained in the healthy persons (healthy 1 and 2, white bars) . As these persons were confirmed to be healthy and samples from these persons thus do not contain antibodies against mycobacterial material, this signal is the result of materials that are unrelated to tuberculosis that do bind to mycolic acid and lead to an ELISA signal. The samples derived from smear negative patients (patients 11-18 (-) , grey bars) show absorbance signals which do not always significantly exceed the signal of the healthy persons.
  • the samples derived from smear positive patients sometimes show absorbance signals are higher than the signal of the healthy persons (patients 1, 2, 4, 5, 6 and 9) , but sometimes signals which are lower than the signal of the healthy persons (patients 3, 7 and 8) .
  • the high background signal derived from materials that are unrelated to tuberculosis but that do bind to mycolic acid thus obscures the signal derived from the actual antibodies that indicate tuberculosis. More importantly, the fact that some of the patients show high signals while some show low signals indicates that detecting binding to immobilised mycolic acids leads to false negative results, which seems to be due to variations between patients. This would mean that in case of carrying out a diagnosis method patients that actually suffer from TB have the risk of being incorrectly dismissed as healthy.
  • Fig. 5 shows that when ELISA tests with rabbit anti-human IgG HRP were performed with immobilised ⁇ -mannosyl phosphomycoketide, the background signal obtained in the healthy persons (healthy 1 and 2, white bars) appears to be markedly lower.
  • the samples derived from smear positive patients (patients 1-9 (+) , black bars) show absorbance signals which are higher than the signal of the healthy persons, thus confirming the presence of specific antibodies that indicate tuberculosis. More importantly, all of the patients 1-9 show a binding signal which is significantly higher than the signal obtained in the healthy persons.
  • the solid substrate of the invention herewith provides a means to reduce the risk of false negative diagnosis in case persons actually suffer from tuberculosis.
  • the signal derived from the actual markers for tuberculosis appears to be significantly less obscured by a background signal than when immobilised mycolic antigens are used, so that the signal derived from the actual markers for tuberculosis becomes more pronounced in particular in case of smear positive patients. This results in a significant improvement with regard to the sensitivity of detection of markers for tuberculosis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un substrat solide comprenant un antigène immobilisé sur ledit substrat, ledit antigène pouvant se lier à un anticorps indiquant la présence d'une substance mycobactérienne chez un être humain ou un animal; elle concerne un procédé pour détecter la présence d'anticorps dirigés contre une substance mycobactérienne dans un échantillon, qui met en oeuvre ledit substrat solide comprenant cet antigène immobilisé. L'invention concerne en outre un biocapteur comprenant ledit substrat solide.
PCT/CN2017/087542 2016-06-08 2017-06-08 Procédé pour détecter la présence d'une substance mycobactérienne dans un échantillon à l'aide d'un antigène de mannosyl-phosphocétide immobilisé WO2017211314A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US16/307,427 US20190302114A1 (en) 2016-06-08 2017-06-08 Method for detecting the presence of mycobacterial material in sample using immobilised mannosyl phosphoketide antigen
RU2018146447A RU2018146447A (ru) 2016-06-08 2017-06-08 Способ детекции присутствия микобактериального материала в образце с использованием иммобилизованного антигена маннозилфосфокетида
CN201780047054.5A CN109791145A (zh) 2016-06-08 2017-06-08 使用固定的甘露糖磷酸化酮抗原检测样品中分枝杆菌物质存在的方法
BR112018075462-5A BR112018075462A2 (pt) 2016-06-08 2017-06-08 método para detectar a presença de material micobacteriano em uma amostra com o uso de um antígeno de manosil fosfocetídeo imobilizado, substrato sólido e biossensor
EP17809753.1A EP3469364A4 (fr) 2016-06-08 2017-06-08 Procédé pour détecter la présence d'une substance mycobactérienne dans un échantillon à l'aide d'un antigène de mannosyl-phosphocétide immobilisé

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
NL2016914A NL2016914B1 (en) 2016-06-08 2016-06-08 Solid substrate comprising antigens immobilised thereto and use thereof in a method for detecting the presence of mycobacterial material in a sample
NL2016913 2016-06-08
NL2016913A NL2016913B1 (en) 2016-06-08 2016-06-08 Solid substrate comprising antigens immobilised thereto and use thereof in a method for detecting the presence of mycobacterial material in a sample
NL2016914 2016-06-08
NL2017204 2016-07-21
NL2017204A NL2017204B1 (en) 2016-06-08 2016-07-21 Solid substrate comprising antigens immobilised thereto, biosensor comprising said solid substrate and method for detecting the presence of mycobacterial material in a sample

Publications (1)

Publication Number Publication Date
WO2017211314A1 true WO2017211314A1 (fr) 2017-12-14

Family

ID=60577600

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/CN2017/087542 WO2017211314A1 (fr) 2016-06-08 2017-06-08 Procédé pour détecter la présence d'une substance mycobactérienne dans un échantillon à l'aide d'un antigène de mannosyl-phosphocétide immobilisé
PCT/CN2017/087547 WO2017211316A1 (fr) 2016-06-08 2017-06-08 Procédé de détection de la présence d'une substance mycobactérienne dans un échantillon au moyen d'au moins deux antigènes

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/087547 WO2017211316A1 (fr) 2016-06-08 2017-06-08 Procédé de détection de la présence d'une substance mycobactérienne dans un échantillon au moyen d'au moins deux antigènes

Country Status (1)

Country Link
WO (2) WO2017211314A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2021443B1 (en) * 2018-08-08 2020-02-20 Kei International Ltd Synthetic antigens for tuberculosis detection
WO2020119669A1 (fr) * 2018-12-10 2020-06-18 Kei International Limited Feuille de nitrocellulose comprenant des immunoglobulines immobilisées et des antigènes à base de lipides et son utilisation
US11243204B2 (en) 2016-06-08 2022-02-08 Kei International Limited Method for detecting the presence of mycobacterial material in a sample using at least two antigens
NL2027721B1 (en) 2021-03-08 2022-09-26 Tomorrows Ip Ltd Method of preparing a detection substrate, detection substrate, and uses thereof
RU2794855C1 (ru) * 2022-01-24 2023-04-25 Федеральное государственное бюджетное научное учреждение "Центральный научно-исследовательский институт туберкулеза" Способ диагностики туберкулеза

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994014069A1 (fr) 1992-12-17 1994-06-23 Kreatech Biotechnology B.V. Procede et dispositif d'identification d'une espece mycobacterienne a l'origine d'une infection mycobacterienne
WO1999012562A1 (fr) * 1997-09-12 1999-03-18 Brigham & Women's Hospital Antigenes synthetiques permettant de provoquer une reponse immunitaire limitee aux cd1
US6416962B1 (en) * 1995-11-20 2002-07-09 Kreatech Biotechnology B.V. Method and device for identifying a mycobacterium species responsible for a mycobacterial infection
US20030143652A1 (en) 2002-01-30 2003-07-31 The Gov. Of The Usa As Represented By The Navy Naval Medical Research Center Office Of Counsel Rapid lateral flow assay for determining exposure to mycobacterium tuberculosis and other mycobacteria
WO2005116654A1 (fr) 2004-05-13 2005-12-08 University Of Pretoria Methode de detection d'une infection mycobacterienne
US20070243557A1 (en) * 2005-10-07 2007-10-18 Friedman Richard L Rapid tuberculosis detection method
US20080064051A1 (en) * 2004-07-21 2008-03-13 Centre For Dna Fingerprinting And Diagnostics Method of Diagnosing Tuberculosis
EP1950218A1 (fr) 2007-01-24 2008-07-30 Centre National de la Recherche Scientifique Antigènes sulfoglycolipidiques, leur procédé de préparation et leur utilisation contre la tuberculose
WO2009133378A2 (fr) 2008-05-02 2009-11-05 Cancer Research Technology Ltd. Produits et procédés permettant de stimuler une réponse immunitaire
WO2010008667A1 (fr) 2008-06-25 2010-01-21 Baxter International Inc Procédés de fabrication de résines antimicrobiennes
CN102707053A (zh) * 2012-06-07 2012-10-03 上海交通大学 一种应用于结核病快速诊断的糖芯片、其制备方法及采用其的结核病诊断试剂盒
WO2012151039A2 (fr) * 2011-05-02 2012-11-08 The Regents Of The University Of California Compositions et procédés pour détecter une mycobactérie
CN102818889A (zh) * 2011-06-09 2012-12-12 上海伊思柏生物科技有限公司 检测结核杆菌脂阿拉伯甘露聚糖特异性抗体的方法
WO2013186679A1 (fr) 2012-06-11 2013-12-19 University Of Pretoria Composition de liposomes comprenant un lipide à modification stérol et composant de paroi cellulaire lipidique mycobactérien purifié et son utilisation dans le diagnostic de la tuberculose
WO2014210327A1 (fr) 2013-06-27 2014-12-31 The Brigham And Women's Hospital, Inc. Procédés et systèmes pour déterminer une infection par m. turberculosis
WO2016024116A1 (fr) 2014-08-13 2016-02-18 Bangor University Kit et procédé

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721109A (en) * 1989-01-18 1998-02-24 Sawai Pharmaceutical Co., Ltd. Method for diagnosing infection caused by acid-fast bacterium

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994014069A1 (fr) 1992-12-17 1994-06-23 Kreatech Biotechnology B.V. Procede et dispositif d'identification d'une espece mycobacterienne a l'origine d'une infection mycobacterienne
US6416962B1 (en) * 1995-11-20 2002-07-09 Kreatech Biotechnology B.V. Method and device for identifying a mycobacterium species responsible for a mycobacterial infection
WO1999012562A1 (fr) * 1997-09-12 1999-03-18 Brigham & Women's Hospital Antigenes synthetiques permettant de provoquer une reponse immunitaire limitee aux cd1
US20030143652A1 (en) 2002-01-30 2003-07-31 The Gov. Of The Usa As Represented By The Navy Naval Medical Research Center Office Of Counsel Rapid lateral flow assay for determining exposure to mycobacterium tuberculosis and other mycobacteria
WO2005116654A1 (fr) 2004-05-13 2005-12-08 University Of Pretoria Methode de detection d'une infection mycobacterienne
US20080064051A1 (en) * 2004-07-21 2008-03-13 Centre For Dna Fingerprinting And Diagnostics Method of Diagnosing Tuberculosis
US20070243557A1 (en) * 2005-10-07 2007-10-18 Friedman Richard L Rapid tuberculosis detection method
EP1950218A1 (fr) 2007-01-24 2008-07-30 Centre National de la Recherche Scientifique Antigènes sulfoglycolipidiques, leur procédé de préparation et leur utilisation contre la tuberculose
WO2009133378A2 (fr) 2008-05-02 2009-11-05 Cancer Research Technology Ltd. Produits et procédés permettant de stimuler une réponse immunitaire
WO2010008667A1 (fr) 2008-06-25 2010-01-21 Baxter International Inc Procédés de fabrication de résines antimicrobiennes
WO2012151039A2 (fr) * 2011-05-02 2012-11-08 The Regents Of The University Of California Compositions et procédés pour détecter une mycobactérie
CN102818889A (zh) * 2011-06-09 2012-12-12 上海伊思柏生物科技有限公司 检测结核杆菌脂阿拉伯甘露聚糖特异性抗体的方法
CN102707053A (zh) * 2012-06-07 2012-10-03 上海交通大学 一种应用于结核病快速诊断的糖芯片、其制备方法及采用其的结核病诊断试剂盒
WO2013186679A1 (fr) 2012-06-11 2013-12-19 University Of Pretoria Composition de liposomes comprenant un lipide à modification stérol et composant de paroi cellulaire lipidique mycobactérien purifié et son utilisation dans le diagnostic de la tuberculose
WO2014210327A1 (fr) 2013-06-27 2014-12-31 The Brigham And Women's Hospital, Inc. Procédés et systèmes pour déterminer une infection par m. turberculosis
WO2016024116A1 (fr) 2014-08-13 2016-02-18 Bangor University Kit et procédé

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ASTARIE-DEQUEKER, G. ET AL., DRUG DISCOVERY TODAY:DISEASE MECHANISMS, vol. 7, no. 1, pages e33 - e41
BUTER JHEIJNEN DWAN ICBICKELHAUPT FMYOUNG DCOTTEN EMOODY DBMINNAARD AJ, J ORG CHEM., 11 July 2016 (2016-07-11)
D. GEERDINKB. TER HORSTM. LEPOREL. MORIG. PUZOA.K. H. HIRSCHM. GILLERONG. DE LIBEROA. J. MINNAARD, CHEM. SCI., 2013, pages 709 - 716
E. LAYRE ET AL., PROC. NATL. ACAD. SCI. (PNAS, vol. 111, no. 8, pages 2978 - 2983
JONG ANNEMIEKE ET AL.: "CDlc Presentation of Synthetic Glycolipid Antigens with Foreign Alkyl Branching Motifs", CHEMISTRY & BIOLOGY, vol. 14, no. 11, 26 November 2007 (2007-11-26), pages 1232 - 1242, XP022348807 *
LI N-S ET AL., JOURNAL OF ORGANIC CHEMISTRY, vol. 78, no. 12, pages 5970 - 5986
MOODY D.BRANCH ET AL.: "CD 1c-mediated T- cell recognition of isoprenoid glycolipids in Mycobacterium tuberculosis infection", NATURE, vol. 404, 20 April 2000 (2000-04-20), pages 884 - 888, XP002192364 *
See also references of EP3469364A4 *
VAN SUMMEREN RUBEN P. ET AL., JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 128, no. 14, pages 4546 - 4547
VAN SUMMEREN, R. P.MOODY, D. B.FERINGA, B. L.MINNAARD, A. J.SUMMEREN, R. P. V.FERINGA, B., JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 12 April 2006 (2006-04-12)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11243204B2 (en) 2016-06-08 2022-02-08 Kei International Limited Method for detecting the presence of mycobacterial material in a sample using at least two antigens
NL2021443B1 (en) * 2018-08-08 2020-02-20 Kei International Ltd Synthetic antigens for tuberculosis detection
EP3833977A4 (fr) * 2018-08-08 2022-06-15 Kei International Limited Antigènes synthétiques pour la détection de la tuberculose
US12031980B2 (en) 2018-08-08 2024-07-09 Kei International Limited Synthetic antigens for tuberculosis detection
WO2020119669A1 (fr) * 2018-12-10 2020-06-18 Kei International Limited Feuille de nitrocellulose comprenant des immunoglobulines immobilisées et des antigènes à base de lipides et son utilisation
NL2027721B1 (en) 2021-03-08 2022-09-26 Tomorrows Ip Ltd Method of preparing a detection substrate, detection substrate, and uses thereof
RU2794855C1 (ru) * 2022-01-24 2023-04-25 Федеральное государственное бюджетное научное учреждение "Центральный научно-исследовательский институт туберкулеза" Способ диагностики туберкулеза

Also Published As

Publication number Publication date
WO2017211316A1 (fr) 2017-12-14

Similar Documents

Publication Publication Date Title
US4847199A (en) Agglutination immunoassay and kit for determination of a multivalent immune species using a buffered salt wash solution
JP6742978B2 (ja) ラテラルフローおよび関連する免疫アッセイにおけるシグナル増幅
US11243204B2 (en) Method for detecting the presence of mycobacterial material in a sample using at least two antigens
EP0280559B1 (fr) Essai immunologique d'agglutination et trousse de réactifs pour la détermination d'une espèce immunollogique polyvalente utilisant une solution saline de nettoyage tamponnée
WO2017211314A1 (fr) Procédé pour détecter la présence d'une substance mycobactérienne dans un échantillon à l'aide d'un antigène de mannosyl-phosphocétide immobilisé
JP2004511807A (ja) 体液サンプル中のｒｓウイルスに関連した生物学的細胞の直接的検出のためのアッセイ
US10921322B2 (en) Methods for detecting a marker for active tuberculosis
Serebrennikova et al. Enhancement of the sensitivity of a lateral flow immunoassay by using the biotin–streptavidin system
JP4323318B2 (ja) ヘリコバクターピロリを検出するための非侵襲的方法
JPH0792460B2 (ja) 抽出組成物として界面活性剤混合物を使用する歯周病に随伴する微生物検出用キットおよびその検出方法
US12031980B2 (en) Synthetic antigens for tuberculosis detection
NL2016913B1 (en) Solid substrate comprising antigens immobilised thereto and use thereof in a method for detecting the presence of mycobacterial material in a sample
NL2016914B1 (en) Solid substrate comprising antigens immobilised thereto and use thereof in a method for detecting the presence of mycobacterial material in a sample
WO2017143985A1 (fr) Procédé de détection d'un marqueur de la tuberculose active
EP0280557B1 (fr) Trousse de réactifs d'essai, dispositif d'extraction et méthode pour la détermination d'antigène A de streptocoques
CA2028146A1 (fr) Composition contenant un anticorps antistreptocoques etiquete, trousse d'analyse et dosage
JP2931111B2 (ja) 癌診断剤
JPH07181191A (ja) 原子間力探針プローブを用いた物質間の親和性の測定方法
WO2009111878A1 (fr) Quantification et caractérisation d'affinité d'anticorps pour le diagnostic d'une maladie à l'aide de la diffraction optique
Dulay Francisella tularensis antibodies
JPH04212062A (ja) アクチノバシラス・アクチノマイセテムコミタンスに対する抗体組成物およびその診断における使用
JP2002275199A (ja) 抗体作製方法及び抗酸菌の免疫学的検出方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17809753

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018075462

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2017809753

Country of ref document: EP

Effective date: 20190108

ENP Entry into the national phase

Ref document number: 112018075462

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20181207